• Publications
  • Influence
Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 *
The Zar Review Group: I.J. Bousquet, N. Khaltaev, A. R. Rabe, J. Rosado-Pinto, G. Scadding, F. Simons, E. Togias, T. Valovirta, P. Vandenplas, D. Wang, M. Stoloff, O. Williams.
Revised nomenclature for allergy for global use: Report of the Nomenclature Review Committee of the World Allergy Organization, October 2003.
The nomenclature proposed in the October 2003 report of the Nomenclature Review Committee of the World Allergy Organization is an update of the European Academy of Allergology and Clinical Immunology
Tiotropium in asthma poorly controlled with standard combination therapy.
In patients with poorly controlled asthma despite the use of inhaled glucocorticoids and LABAs, the addition of tiotropium significantly increased the time to the first severe exacerbation and provided modest sustained bronchodilation.
Withdrawal of inhaled glucocorticoids and exacerbations of COPD.
In patients with severe COPD receiving tiotropium plus salmeterol, the risk of moderate or severe exacerbations was similar among those who discontinued inhaled glucocorticoids and those who continued glucocORTicoid therapy, but there was a greater decrease in lung function during the final step of glucoc Corticoid withdrawal.
Once-daily indacaterol versus twice-daily salmeterol for COPD: a placebo-controlled comparison
Once-daily treatment with 150 &mgr;g indacaterol had a significant and clinically relevant bronchodilator effect over 24 h post-dose and improved health status and dyspnoea to a greater extent than twice-daily 50 &mGr;g salmeterol.
Uniform definition of asthma severity, control, and exacerbations: document presented for the World Health Organization Consultation on Severe Asthma.
Asthma is a global health problem affecting around 300 million individuals of all ages, ethnic groups and countries, and a common international approach is favored to define severe asthma, uncontrolled asthma, and when the 2 coincide, although adaptation may be required in accordance with local conditions.
Efficacy of a new once-daily long-acting inhaled β2-agonist indacaterol versus twice-daily formoterol in COPD
Once-daily indacaterol is an effective 24’h bronchodilator that improves symptoms and health status and confers clinical improvements over a twice-daily 12 h LABA as a treatment for patients with moderate to severe COPD.
SQ-standardized sublingual grass immunotherapy: confirmation of disease modification 2 years after 3 years of treatment in a randomized trial.
Disease modification by SQ-standardized grass allergy immunotherapy tablet is confirmed by long-lasting significant effects on the allergen-specific antibody response in addition to effective symptomatic treatment of allergic rhinoconjunctivitis.
Efficacy and safety of sublingual immunotherapy with grass allergen tablets for seasonal allergic rhinoconjunctivitis.
Sublingual immunotherapy with grass allergen tablets was effective in grass pollen-induced rhinoconjunctivitis and represents a safe alternative to injection immunotherapy suitable for home use.